Vir Biotechnology (NASDAQ:VIR) CAO Sells $13,626.05 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,829 shares of Vir Biotechnology stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $7.45, for a total value of $13,626.05. Following the completion of the transaction, the chief accounting officer owned 71,043 shares in the company, valued at $529,270.35. This trade represents a 2.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Brent Sabatini also recently made the following trade(s):

• On Friday, February 13th, Brent Sabatini sold 1,530 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.79, for a total transaction of $11,918.70.

Vir Biotechnology Trading Up 27.7%

Shares of NASDAQ:VIR traded up $2.06 during trading on Tuesday, reaching $9.49. The stock had a trading volume of 38,240,174 shares, compared to its average volume of 1,972,225. The firm’s 50-day simple moving average is $6.80 and its 200 day simple moving average is $5.99. Vir Biotechnology, Inc. has a one year low of $4.16 and a one year high of $10.29. The company has a market capitalization of $1.32 billion, a P/E ratio of -3.00 and a beta of 1.69.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The company had revenue of $64.07 million during the quarter, compared to analysts’ expectations of $19.91 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 47.14%. Vir Biotechnology’s revenue for the quarter was up 417.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.76) earnings per share. Equities research analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Institutional Trading of Vir Biotechnology

Large investors have recently added to or reduced their stakes in the company. Corient Private Wealth LLC increased its holdings in shares of Vir Biotechnology by 1.0% in the fourth quarter. Corient Private Wealth LLC now owns 262,211 shares of the company’s stock valued at $1,572,000 after purchasing an additional 2,515 shares during the period. Virtus Investment Advisers LLC lifted its holdings in shares of Vir Biotechnology by 82.4% during the fourth quarter. Virtus Investment Advisers LLC now owns 39,764 shares of the company’s stock worth $240,000 after purchasing an additional 17,966 shares during the period. Tudor Investment Corp ET AL purchased a new stake in Vir Biotechnology in the fourth quarter valued at approximately $414,000. Polymer Capital Management US LLC acquired a new position in Vir Biotechnology in the 4th quarter worth approximately $202,000. Finally, Quadrature Capital Ltd acquired a new position in Vir Biotechnology in the 4th quarter worth approximately $300,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

More Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration: Vir announced a global co‑development/co‑commercialization collaboration with Astellas for prostate cancer candidate VIR‑5500 that includes $335M upfront/near‑term payments, up to $1.37B in additional milestones, a 50/50 U.S. profit/loss split, Astellas leading U.S. commercialization and ex‑U.S. rights, plus tiered double‑digit ex‑U.S. royalties — a major de‑risking and validation event for the program. Read More.
• Positive Sentiment: Encouraging Phase 1 VIR‑5500 data: Updated trial results show a favorable safety profile and meaningful activity (reported ORR ~45% at higher doses in later cohorts), supporting the value of the asset and underpinning the Astellas deal. Read More.
• Positive Sentiment: Quarterly beat and strong revenue growth: Q4 EPS of ($0.31) beat estimates and revenue of $64.1M significantly exceeded the consensus (~$19.9M), with revenue up ~418% year‑over‑year — evidence of commercial traction and stronger near‑term financial performance. Read More.
• Positive Sentiment: Analyst upgrade: Needham raised its price target to $18 and maintained a buy rating, adding institutional validation and support for higher upside expectations. Read More.
• Neutral Sentiment: Broad media coverage and analyst commentary: Multiple outlets (Forbes, Seeking Alpha, MSN) are highlighting the deal, data and earnings beat — amplifying attention and trading volume but not adding new fundamentals. Read More.
• Neutral Sentiment: Company disclosures and materials: Earnings call transcript and slide deck provide more color on pipeline prioritization (HDV, oncology) and capital deployment plans. Read More.
• Negative Sentiment: Proposed public offering: Vir filed to sell additional shares, which can be dilutive and weigh on near‑term share price despite the cash proceeds. Read More.
• Negative Sentiment: Ongoing losses and wide negative margins: The company reported a large 2025 net loss (and very negative margins), so long‑term value depends on successful development/commercial execution and milestone/cash management. Read More.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Raymond James Financial upgraded Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 target price on the stock in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Vir Biotechnology in a research note on Tuesday, December 30th. Morgan Stanley upped their price objective on shares of Vir Biotechnology from $20.00 to $24.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Evercore reiterated an “outperform” rating and issued a $18.00 target price on shares of Vir Biotechnology in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.88.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.